Fresh data from a mid-stage clinical trial provide further evidence that berobenatide, an obesity drug Pfizer acquired from Metsera, may be viable as a monthly dose. However, questions remain regarding its competitiveness against existing and upcoming weekly injectables that may offer superior weight loss results.
In the VESPER-3 study, participants with obesity received weekly doses of berobenatide for 12 weeks before transitioning to higher monthly doses through week 28. According to previous Pfizer reports, patients who completed the treatment saw weight loss of up to 12.1%.
Data presented Saturday at the American Diabetes Association’s annual meeting indicate that the rate of weight loss remained consistent during the transition from weekly to monthly dosing, with no plateau observed by the 28-week mark. While these results are encouraging, the weight loss rate at 28 weeks still trails the results seen at a comparable stage in Eli Lilly’s pivotal trial for Zepbound.
Also Read
- Why Weight Loss Medication Alone Are Not Enough: How Ongoing Care Helps Fill The Medical Weight Loss Gap
- Democrats Seek To Spotlight Rising Health Costs by Forcing Vote on Trump Regulation
- Sierra Leone’s first lady refuses to condemn FGM without ‘reliable data’ on harms
- FDA Staff Weighs In on Potential First mRNA Flu Shot
